Filing Flows › Janux Therapeutics (JANX) › Q2 2026 › vs Q1 2026
Janux Therapeutics (JANX) Q2 2026 vs Q1 2026 (quarter over quarter)
Janux Therapeutics's revenue rose $6.5M (+175%) from $3.7M in Q1 2026 to $10.3M in Q2 2026.
Janux Therapeutics, Q2 2026: revenue $10.3M, operating margin -308.7%, net loss $22.0M, operating cash flow $12.5M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 119.6% | -337.8% | +457.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $10.3M | $3.7M | $6.5M | +175% |
| Other income, net | $9.7M | $9.9M | −$134K | -1% |
| Net loss | $22.0M | $24.4M | −$2.4M | -10% |
| Costs & expenses | $42.0M | $37.9M | $4.0M | +11% |
| Operating costs | $42.0M | $37.9M | $4.0M | +11% |
| Research & development | $31.0M | $26.8M | $4.2M | +16% |
| General & admin | $11.0M | $11.1M | −$170K | -2% |
| Operating cash sources | $34.5M | $12.0M | $22.4M | +187% |
| Depreciation | $463K | $469K | −$6K | -1% |
| Share-based compensation | $9.1M | $9.3M | −$207K | -2% |
| Working capital & other | $24.9M | $2.3M | $22.6M | +991% |
| Net loss absorbed | $22.0M | $24.4M | −$2.4M | -10% |
| Operating cash flow | $12.5M | −$12.3M | $24.8M | — |
| Free cash flow (OCF − capex) | $12.3M | −$12.6M | $24.9M | — |
| Capital expenditures | $202K | $273K | −$71K | -26% |
Questions
How much did Janux Therapeutics's revenue grow quarter over quarter in Q2 2026?
Janux Therapeutics's revenue rose $6.5M (+175%) from $3.7M in Q1 2026 to $10.3M in Q2 2026.